Immune modulation of T-cell and NK (natural killer) cell activities by TEXs (tumour-derived exosomes)

Biochemical Society Transactions

Volumn 41, Issue 1, 2013, Pages 245-251

  Whiteside, Theresa L ^a  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

Immune suppression; Natural killer cell (NK cell); T cell; Tumour escape; Tumour derived exosome (TEX)

Indexed keywords

CD16 ANTIGEN; CD3 ANTIGEN; CD33 ANTIGEN; CD34 ANTIGEN; CD56 ANTIGEN; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; FAS ANTIGEN; FAS LIGAND; GRANZYME B; INTERLEUKIN 10; INTERLEUKIN 2 RECEPTOR ALPHA; JANUS KINASE 3; NATURAL KILLER CELL RECEPTOR NKG2D; PERFORIN; SMAD PROTEIN; STEM CELL FACTOR RECEPTOR; TRANSCRIPTION FACTOR FOXP3; TRANSFORMING GROWTH FACTOR BETA1;

ACUTE GRANULOCYTIC LEUKEMIA; ANTIGEN EXPRESSION; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; CANCER PATIENT; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL EXPANSION; COCULTURE; CONFERENCE PAPER; CONTROLLED STUDY; CYTOPATHOGENIC EFFECT; DOWN REGULATION; EXOSOME; HUMAN; HUMAN CELL; IMMUNOCOMPETENT CELL; IMMUNOLOGICAL TOLERANCE; IMMUNOMODULATION; LYMPHOCYTE DIFFERENTIATION; LYMPHOCYTE PROLIFERATION; NATURAL KILLER CELL; PRIORITY JOURNAL; PROGNOSIS; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; REGULATORY T LYMPHOCYTE; SIGNAL TRANSDUCTION; SOLID TUMOR; SUPERNATANT; T LYMPHOCYTE; TUMOR CELL; TUMOR DERIVED EXOSOME; TUMOR ESCAPE; TUMOR GROWTH; TUMOR IMMUNITY;

APOPTOSIS; CELL DIFFERENTIATION; EXOSOMES; HUMANS; KILLER CELLS, NATURAL; NEOPLASMS; SIGNAL TRANSDUCTION; T-LYMPHOCYTES, REGULATORY;

EID: 84873149964     PISSN: 03005127     EISSN: 14708752     Source Type: Journal    
DOI: 10.1042/BST20120265     Document Type: Conference Paper

References (50)

1. Peinado, H., Alecković, M., Lavotshkin, S., Matei, I., Costa-Silva, B., Moreno-Bueno, G., Hergueta-Redondo, M., Williams, C., Garćia-Santos, G., Ghajar, C. et al. (2012) Melanoma exosomes educate bone marrow progenitor cells toward a pro-metastatic phenotype through MET. Nat. Med. 18, 883-891
2. Somasundaram, R. and Herlyn, M. (2012) Melanoma exosomes: messengers of metastasis. Nat. Med. 18, 853-854
3. Cocucci, E., Racchetti, G. and Meldolesi, J. (2011) Shedding microvesicles: artefacts no more. Trends Cell Biol. 19, 43-51
4. Whiteside, T. L., Mandapathil, M., Szczepanski, M. and Szajnik, M. (2011) Mechanisms of tumor escape from the immune system: adenosine-producing Treg, exosomes and tumor-associated TLRs. Bull. Cancer 98, E25-E31
5. Whiteside, T. L. (2006) Immune suppression in cancer: effects on immune cells, mechanisms and future therapeutic intervention. Semin. Cancer Biol. 16, 3-15 (Pubitemid 43139705)
6. Huber, V., Fais, S., Iero, M., Lugini, L., Canese, P., Squarcina, P., Zaccheddu, A., Colone, M., Arancia, G. and Gentile, M. (2005) Human colorectal cancer cells induce T-cell death through release of proapoptotic microvesicles: role in immune escape. Gastroenterology 128, 1796-1804 (Pubitemid 40824690)
7. Kim, J. W., Wieckowski, E., Taylor, D. D., Reichert, T. E., Watkins, S. and Whiteside, T. L. (2005) Fas ligand-positive membranous vesicles isolated from sera of patients with oral cancer induce apoptosis of activated T lymphocytes. Clin. Cancer Res. 11, 1010-1020 (Pubitemid 40175748)
8. Chaput, N. and Théry, C. (2011) Exosomes: immune properties and potential clinical implementations. Semin. Immunopathol. 33, 419-440
9. Thery, C., Zitvogel, L. and Amigorena, S. (2002) Exosomes: composition, biogenesis and function. Nat. Rev. Immunol. 2, 569-579 (Pubitemid 37328732)
10. Wieckowski, E. and Whiteside, T. L. (2006) Human tumor-derived vs dendritic cell-derived exosomes have distinct biologic roles and molecular profiles. Immunol. Res. 36, 247-254 (Pubitemid 46398601)
11. Record, M., Subra, C., Silvente-Poirot, S. and Poirot, M. (2011) Exosomes as intercellular signalosomes and pharmacological effectors. Biochem. Pharmacol. 81, 1171-1182
12. Théry, C., Ostrowski, M. and Segura, E. (2009) Membrane vesicles as conveyors of immune responses. Nat. Rev. Immunol. 9, 581-593
13. Taylor, D. D. and Gercel-Taylor, C. (2005) Tumour-derived exosomes and their role in cancer-associated T-cell signalling defects. Br. J. Cancer 92, 305-311 (Pubitemid 40343146)
14. Clayton, A., Al-Taei, S., Webber, J., Mason, M. D. and Tabi, Z. (2011) Cancer exosomes express CD39 and CD73, which suppress T cells through adenosine production. J. Immunol. 187, 676-683
15. + T lymphocytes. J. Immunol. 183, 3720-3730
16. + exosomes from tumor-bearing mice suppress tumor antigen-specific immune responses. Eur. J. Immunol. 42, 1778-1784
17. Andreola, G., Rivoltini, L., Castelli, C., Huber, V., Perogo, P., Deho, P., Squarcina, P., Accornero, P., Lozupone, F., Lugini, L. et al. (2002) Induction of lymphocyte apoptosis by tumor cell secretion of FasL-bearing microvesicles. J. Exp. Med. 195, 1303-1316 (Pubitemid 34564332)
18. Martínez-Lorenzo, M. J., Anel, A., Alava, M. A., Piñeiro, A., Naval, J., Lasierra, P. and Larrad, L. (2004) The human melanoma cell line MelJuSo secretes bioactive FasL and APO2L/TRAIL on the surface of microvesicles: possible contribution to tumor counterattack. Exp. Cell Res. 295, 315-329 (Pubitemid 38490488)
19. Abrahams, V. M., Straszewski, S. L., Kamsteeg, M., Hanczaruk, B., Schwartz, P. E., Rutherford, T. J. and Mor, G. (2003) Epithelial ovarian cancer cells secrete functional Fas ligand. Cancer Res. 63, 5573-5581 (Pubitemid 37139880)
20. + cells and inhibit cytotoxic T cell activity through CD8 ligation. Eur. J. Immunol. 33, 125-134 (Pubitemid 36157650)
21. Contini, P., Ghio, M., Merlo, A., Poggi, A., Indiveri, F. and Puppo, F. (2005) Apoptosis of antigen-specific T lymphocytes upon the engagement of CD8 by soluble HLA class I molecules is Fas ligand/Fas mediated: evidence for the involvement of p56lck, calcium calmodulin kinase II, and calcium-independent protein kinase C signaling pathways and for NF-κB and NF-AT nuclear translocation. J. Immunol. 175, 7244-7254 (Pubitemid 41713419)
22. + T cells of patients with squamous cell carcinoma of the head and neck. Clin. Cancer Res. 10, 5101-5110 (Pubitemid 39099784)
23. Pardoll, D. M. (2012) The blockade of immune checkpoints in cancer immunotherapy. Nat. Rev. Cancer 12, 252-264
24. Hoffmann, T. K., Dworacki, G., Tsukihiro, T., Meidenbauer, N., Gooding, W., Johnson, J. T. and Whiteside, T. L. (2002) Spontaneous apoptosis of circulating T lymphocytes in patients with head and neck cancer and its clinical importance. Clin. Cancer Res. 8, 2553-2562 (Pubitemid 34856339)
25. Saito, T., Kuss, I., Dworacki, G., Gooding, W., Johnson, J. T. and Whiteside, T. L. (1999) Spontaneous ex vivo apoptosis of peripheral blood mononuclear cells in patients with head and neck cancer. Clin. Cancer Res. 5, 1263-1273 (Pubitemid 29282928)
26. Czystowska, M., Han, J., Szczepanski, M. J., Szajnik, M., Quadrini, K., Brandwein, H., Hadden, J. W., Signorelli, K. and Whiteside, T. L. (2009) IRX-2, a novel immunotherapeutic, protects human T cells from tumor-induced cell death. Cell Death Differ. 16, 708-718
27. Czystowska, M., Szczepanski, M. J., Szajnik, M., Quadrini, K., Brandwein, H., Hadden, J. W. and Whiteside, T. L. (2011) Mechanisms of T-cell protection from death by IRX-2: a new immunotherapeutic. Cancer Immunol. Immunother. 60, 495-506
28. Groneberg, C., Pickartz, T., Binder, A., Ringel, F., Srock, S., Sieber, T., Schoeler, D. and Schriever, F. (2003) Clinical relevance of CD95 (Fas/Apo-1) on T cells of patients with B-cell chronic lymphocytic leukemia. Exp. Hematol. 31, 682-685 (Pubitemid 36945380)
29. Massaia, M., Borrione, P., Attisano, C., Barral, P., Beggiato, E., Montacchini, L., Bianchi, A., Boccadoro, M. and Pileri, A. (1995) Dysregulated Fas and Bcl-2 expression leading to enhanced apoptosis in T cells of multiple myeloma patients. Blood 85, 3679-3687
30. Taylor, D. D., Gercel-Taylor, C., Lyons, K. S., Stanson, J. and Whiteside, T. L. (2003) T-cell apoptosis and suppression of T-cell receptor/CD3-ζ by Fas ligand-containing membrane vesicles shed from ovarian tumors. Clin. Cancer Res. 9, 5113-5119 (Pubitemid 37413559)
31. Szajnik, M., Czystowska, M., Szczepanski, M. J., Mandapathil, M. and Whiteside, T. L. (2010) Tumor-derived microvesicles induce, expand and up-regulate biological activities of human regulatory T cells (Treg). PLoS ONE 5, e11469
32. Valenti, R., Huber, V., Filipazzi, P., Pilla, L., Sovena, G., Villa, A., Corebelli, A., Fais, S., Parmiani, G. and Rivoltini, L. (2006) Human tumor-released microvesicles promote the differentiation of myeloid cells with transforming growth factor-β-mediated suppressive activity on T lymphocytes. Cancer Res. 66, 9290-9298 (Pubitemid 44521151)
33. Nagaraj, S. and Gabrilovich, D. I. (2010) Myeloid-derived suppressor cells in human cancer. Cancer J. 16, 348-353
34. Bauernhofer, T., Kuss, I., Henderson, B., Baum, A. S. and Whiteside, T. L. (2003) Preferential apoptosis of CD56dim natural killer cell subset in patients with cancer. Eur. J. Immunol. 33, 119-124 (Pubitemid 36157649)
35. Szczepanski, M. J., Szajnik, M., Welsh, A., Foon, K. A., Whiteside, T. L. and Boyiadzis, M. (2010) Interleukin-15 enhances natural killer cell cytotoxicity in patients with acute myeloid leukemia by upregulating the activating NK cell receptors. Cancer Immunol. Immunother. 59, 73-79
36. Clayton, A., Mitchell, J. P., Court, J., Linnane, S., Mason, M. D. and Tabi, Z. (2008) Human tumor-derived exosomes down-modulate NKG2D expression. J. Immunol. 180, 7249-7258
37. Clayton, A. and Tabi, Z. (2005) Exosomes and the MICA-NKG2D system in cancer. Blood Cells Mol. Dis. 34, 206-213 (Pubitemid 40693556)
38. Szczepanski, M. J., Szajnik, M., Welsh, A., Whiteside, T. L. and Boyiadzis, M. (2011) Blast-derived microvesicles in sera from patients with acute myeloid leukemia suppress natural killer cell function via membrane-associated transforming growth factor-β1. Haematologica 96, 1302-1309
39. Zhang, H., Conrad, D. M., Butler, J. J., Zhao, C, Blay, J. and Hoskin, D. W. (2004) Adenosine acts through A2 receptors to inhibit IL-2-induced tyrosine phosphorylation of STAT5 in T lymphocytes: role of cyclic adenosine 3', 5'-monophosphate and phosphatases. J. Immunol. 173, 932-944 (Pubitemid 38924266)
40. Deaglio, S., Dwyer, K. M., Gao, W., Friedman, D., Usheva, A., Erat, A., Chen, J. F., Enjyoji, K., Linden, J., Oukka, M. et al. (2007) Adenosine generation catalyzed by CD39 and CD73 expressed on regulatory T cells mediates immune suppression. J. Exp. Med. 204, 1257-1265 (Pubitemid 46919862)
41. Borsellino, G., Kleinewietfeld, M., Di Mitri, D., Sternjak, A., Diamantini, A., Giometto, R., Hopner, S., Centonze, D., Bernardi, G., Dell'Acqua, M. L. et al. (2007) Expression of ectonucleotidase CD39 by Foxp3 + Treg cells: hydrolysis of extracellular ATP and immune suppression. Blood 110, 1225-1232 (Pubitemid 47281420)
42. Mandapathil, M., Szczepanski, M. J., Szajnik, M., Ren, J., Jackson, E. K., Johnson, J. T., Gorelik, E., Lang, S. and Whiteside, T. L. (2010) Adenosine and prostaglandin E2 cooperate in the suppression of immune responses mediated by adaptive regulatory T cells. J. Biol. Chem. 285, 27571-27580
43. Zhang, B. (2010) CD73: a novel target for cancer immunotherapy. Cancer Res. 70, 6407-6411
44. Bergmann, C, Strauss, L., Wieckowski, E., Czystowska, M., Albers, A., Wang, Y., Zeidler, R., Lang, S. and Whiteside, T. L. (2009) Tumor-derived microvesicles in sera of patients with head and neck cancer and their role in tumor progression. Head Neck 31, 371-380
45. Taylor, D. D. and Gercel-Taylor, C. (2011) Exosomes/microvesicles: mediators of cancer-associated immunosuppressive microenvironments. Semin. Immunopathol. 33, 441-454
46. Rivera, Z., Ferrone, S., Wang, X., Jube, S., Yang, H., Pass, H. I., Kanodia, S., Gaudino, G. and Carbone, M. (2012) CSPG4 as a target of antibody-based immunotherapy for malignant mesothelioma. Clin. Cancer Res. 18, 5352-5363
47. Iero, M., Valenti, R., Huber, V., Filipazzi, P., Parmiani, G., Fais, S. and Rivoltini, L (2008) Tumour-released exosomes and their implications in cancer immunity. Cell Death Differ. 15, 80-88 (Pubitemid 350286175)
48. Ichim, T. E., Zhong, Z., Kaushal, S., Zheng, X., Ren, X., Hao, X., Joyce, JA., Hanley, H. H., Riordan, N. H., Koropatnick, J. et al. (2008) Exosomes as a tumor immune escape mechanism: possible therapeutic implications. J. Transl. Med. 6, 37
49. Huber, V., Filipazzi, P., Iero, M., Fais, S. and Rivoltini, L (2008) More insights into the immunosuppressive potential of tumor exosomes. J. Transl. Med. 6, 63
50. Smyth, M. J., Cretney, E., Kershaw, M. H. and Hayakawa, Y. (2004) Cytokines in cancer immunity and immunotherapy. Immunol. Rev. 202, 275-293 (Pubitemid 39576919)